Ventyx Biosciences, Inc.
VTYX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VTYX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2025.
Tracking 4 pipeline candidates · 2 clinical trials for Ventyx Biosciences, Inc..
Similar companies
Run Ventyx Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ventyx Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
32.2 months
D/E 0.10
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Frequently asked questions
What is Ventyx Biosciences, Inc.'s lead drug candidate?
Ventyx Biosciences, Inc.'s most advanced tracked candidate is tamuzimod (Phase 2) for Moderately to severely active ulcerative colitis (UC).
Who is the CEO of Ventyx Biosciences, Inc.?
Raju Mohan, Ph.D. is the chief executive officer of Ventyx Biosciences, Inc. (VTYX).
Where is Ventyx Biosciences, Inc. headquartered?
Ventyx Biosciences, Inc. (VTYX) is headquartered in San Diego, CA, United States.
What therapeutic areas does Ventyx Biosciences, Inc. focus on?
Ventyx Biosciences, Inc. develops therapies across Oncology, Immunology, Cardiovascular, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.